FDA’s Patent And Exclusivity Team Aims To Ensure Timely First Generics
This article was originally published in The Pink Sheet Daily
Generic drugs office will proactively seek litigation and other information that could affect launch timing.
You may also be interested in...
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.
Novavax Readying Multiple COVID-19 Vaccine Candidates To Ensure Fall Availability
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.